Asset profile
CC-223
Small molecule
Evidence outlook · lead readout
NCT01177397 · Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT01177397: The study assigned all 226 participants to CC-223 without randomization, blinding, or a placebo or active comparator. Although it included clinical measures such as 6-month progression-free survival, the primary results were descriptive and the glioblastoma 6-month progression-free survival result was 0% (0 of 13 participants), so the findings provide limited evidence of treatment effectiveness.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.